Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 19/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.82 |
| ▸ | HTR2B | P41595 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798972 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| SCHEMBL2988139 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL152317 | 0.99 | ADRB1 (0.98) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| SCHEMBL154839 | 0.94 | ADRB1 (0.89) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| SCHEMBL2974709 | 0.94 | ADRB1 (0.89) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| SCHEMBL4709183 | 0.94 | ADRB2 (0.95) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL153897 | 0.93 | ADRB1 (0.88) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| SCHEMBL154335 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| SCHEMBL153533 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A | |
| SCHEMBL2989571 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056916-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-06-06 | — | — | US | claimed |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-18 | — | — | US | claimed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2006040279-A1 | PI3 KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006037738-A1 | MODIFYING SURFACES OF LACTOSE SERVING AS AN AUXILIARY AGENT TO BE USED FOR POWDER INHALANTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102350-A1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-06 | — | — | US | disclosed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | ADRB1, ADRB2, ADRB3 | ADRB1 1/4885ADRB2 2/4885CHRM2 13/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ADRB1 90/4885ADRB2 55/4885CHRM2 166/4885 |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | SLC26A4, CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB1 69/4885ADRB2 50/4885CHRM2 6/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ADRB1 308/4885ADRB2 522/4885CHRM2 220/4885 |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ADRB1 38/4885ADRB2 27/4885CHRM2 5/4885 |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, CFTR | ADRB1 115/4885ADRB2 49/4885CHRM2 13/4885 |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | CLIC1, OTC, SLC10A1 | ADRB1 56/4885ADRB2 80/4885CHRM2 85/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ADRB1 308/4885ADRB2 522/4885CHRM2 220/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | ADRB1 73/4885ADRB2 11/4885CHRM2 10/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ADRB1 90/4885ADRB2 55/4885CHRM2 166/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ADRB1 308/4885ADRB2 522/4885CHRM2 220/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ADRB1 1307/4885ADRB2 1836/4885CHRM2 971/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ADRB1 90/4885ADRB2 55/4885CHRM2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.